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Background
Previous animal model studies from Sukumar and others
demonstrated the effect of intraductal administration of
cytotoxic agents in preventing the occurrence of breast
cancer. To determine the feasibility of the approach in
humans, a preliminary study was performed in patients
who were diagnosed with breast cancer and were waiting
for mastectomy. Two drugs, carboplatin and Pegylated
Liposomal Doxorubicin (PLD) were tested. These drugs
were selected based on the results of preclinical studies.
This report presents findings of histopathological exami-
nation of breast tissue taken from patients received intra-
ductal administration of these two agents.
Methods
This was an uncontrolled observational dose escalation
study. A total of 31 subjects undergoing mastectomy for
breast carcinoma were included in this study. There were
15 subjects in the Carboplatin arm, and these 15 were
divided into 3 dosage groups (60, 120, and 300 mg), with
5 subjects per dosage group. There were 16 subjects in the
PLD arm (one patient was withdrawn because of a central
lesion which precluded duct cannulation) and they were
also divided into 3 dosage groups (10, 20, 50 mg). The 30
subject's age ranged from 25.9 years to 75.6 years. After
intraductal injection of drugs into patients for at least 24
hours (up to 5 days), mastectomy was performed and
specimens were processed in the pathology laboratory.
Specific attention was paid to compare the cannulated
ducts (dye stained ducts) with non-cannulated ducts (no-
dye stained ducts) for inflammatory response and ductal
epithelial changes (eosinophilic cytoplasm, nucleoli, loss
of epithelium), each scored as none, mild, moderate, to
severe using routine HE sections. The examination was
performed without specific knowledge of dose levels for
each drug by two pathologists (JYR and HYY).
Results/conclusion
For Carboplatin group, there was a dose-response increase
of inflammatory response at the levels of mild to moder-
ate degree. There was also a dose-response increase in the
ductal epithelial cell changes (P < 0.05 for both). For PLD
group, no severe inflammatory changes were seen in any
dose group, and a non-significant trend (P > 0.05) of
increased for mild to moderate inflammatory response
was seen in nipple, in dye stained ducts, and stromal tis-
sue. There was a significant increase (P < 0.05) of epithe-
lial response to the PLD treatment in ducts with dye versus
ducts without dye in any given dose. However, the low
dose level appeared to have more "mild" to "moderate"
degree of change whereas the high dose group showed
more "severe" epithelial cell change. No changes were
seen in ducts without dye in the high dose group.
Together, short term intraductal treatment of cytotoxic
agents may induce some degree of epithelial changes and
some inflammatory response. However, the long term
effect remains to be determined.
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